3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
10
Meningioma
4
Gastro-enteropancreatic neuroendocrine tumor
3
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Medulloblastoma
2
Glioma
2
Ependymoma
2
Adenoma, Islet Cell
2
Stomach Neoplasms
1
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Diseases
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hypertension
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Interventions
Temozolomide
45
Radiotherapy
17
Magnetic Resonance Spectroscopy
17
Specimen Handling
14
Bevacizumab
12
pembrolizumab
11
Lomustine
9
Radiation
8
fludarabine
7
Cyclophosphamide
7
atezolizumab
4
Biopsy
4
olaparib
3
Transurethral Resection of Bladder
3
Surgical Procedures, Operative
3
Nivolumab
3
Leukapheresis
3
D2C7-(scdsFv)-PE38KDEL
3
Blood Specimen Collection
3
Aminolevulinic Acid
3
regorafenib
2
fluciclovine F-18
2
contrast agent BR1
2
antisecretory factor
2
abemaciclib
2
Restraint, Physical
2
Re-Irradiation
2
Radiation Dose Hypofractionation
2
Palliative Care
2
Oncolytic Virotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Glioblastoma
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled